Global Lung Cancer
Therapeutics Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2015
Future Market Insights
www.futuremarketinsights.com
sales@futuremarketinsights.com
Report
Description
Report Description
Lung cancer is a malignant tumor characterized by uncontrolled growth of cell tissues in
the lung. Itis the second most commonly diagnosed and has the highest mortality rate of
all cancers in both men and women. American Lung Association has estimated that
around 224,210new cases were diagnosed with lung cancer in the American region that
accounts for approximately 13% of all the cancer cases diagnosed. Thus, with the rise in
incidence rate of lung cancer, the demand for therapeutics is also expected to grow
during the study period.
Based on the cancer cell types, lung cancer is broadly segmented as small cell lung cancer
and non-small cell lung cancer (NSCLC). NSCLC segment accounts for approximately 80 to
90% of all lung cancers. Based on the cell shape and size, NSCLC is further divided to
three subtypes, they are adenocarcinoma, large-cell carcinoma and squamous cell
carcinoma. These NSCLC’s are primarily treated with the surgeries, at the same time
chemotherapy is increasingly used for both pre-operative and post-operative treatment
of the patients. The treatment options available for the NSCLC include surgery, radiation
therapy and chemotherapy. As per the American Cancer Society, it was estimated that in
the United States approximately 195,000 peopleare suffering from NSCLC every year and
the number of deaths from NSCLC are approximately 135,000. The top five global brands
that are commercially available in the market are Avastin, Tarceva, Alimta, Gemzar and
Taxotere. Thus, all the above mentioned factors collectively drive the growth of the global
lung cancer therapeutics market.
Browse Full Report@...